Pendal Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pendal Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,615	Closed	-$465K	–	458
2022 Q2	$465K	Buy	+5,615	New	+$447K	﹤0.01%	360
2019 Q4	–	Sell	-11,429	Closed	-$770K	–	447
2019 Q3	$770K	Sell	11,429 -921	-7%	-$70.9K	0.01%	317
2019 Q2	$1.06M	Buy	12,350 +622	+5%	+$53.2K	0.01%	273
2019 Q1	$1.04M	Hold	11,728	–	–	0.01%	290
2018 Q4	$999K	Sell	11,728 -5	-0%	-$476	0.02%	267
2018 Q3	$1.14M	Hold	11,733	–	–	0.02%	281
2018 Q2	$1.11M	Sell	11,733 -13	-0.1%	-$1.14K	0.01%	292
2018 Q1	$952K	Buy	11,746 +161	+1%	+$13.8K	0.01%	328
2017 Q4	$1.03M	Buy	11,585 +512	+5%	+$44.5K	0.01%	297
2017 Q3	$1.03M	Buy	11,073 +4,463	+68%	+$394K	0.01%	305
2017 Q2	$600K	Buy	+6,610	New	+$601K	0.01%	346

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Pendal Group's BMRN Position: Q3 2022 in Review

Pendal Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 5,615 shares — an estimated $465K sold.

Pendal Group first reported a position in BMRN in Q2 2017 and held it in 11 quarters. The position peaked at $1.14M in Q3 2018. 552 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Pendal Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Pendal Group sold 5,615 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $465K.
Pendal Group first reported a position in BioMarin Pharmaceuticals in Q2 2017 and held it in 11 quarters.
Pendal Group's BioMarin Pharmaceuticals position peaked at $1.14M in Q3 2018.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Pendal Group's 13F filing for Q3 2022, filed 18 Oct 2022.